The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4 (DPP-4), is not well established. 16492 patients were randomized diagnosed with type 2 diabetes with a history of cardiovascular events or high risk to receive saxagliptin or placebo. Other medications for diabetes, including hypoglycemic, were permitted. The combined...
Original title: Clinical Outcome Following Stringent Discontinuation of Dual Anti-Platelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents: Two-Year Follow-up of the Randomized TWENTE Trial. Reference: Keneth T, Hanim S, et al. J Am Coll Cardiol 2013. Article in press. In recent years there have been new drug-eluting...
Original title: Comparison of 30-Day and 5-Year Outcomes of Percutaneous Coronary Intervention Versus Coronary Bypass Grafting in Patients Aged ≤50 Years. Reference: Fausto Biancari, et al. Am J Cardiology Article in Press. Coronary artery bypass grafting (CABG) is associated with better evolution than percutaneous coronary intervention (PCI), mainly due to left main and multiple vessels re...
Original title: Drug-eluting stents in patients on chronic haemodialysis: Paclitaxel-eluting stents vs. limus –eluting stents Reference: Gabriel l. Sardi, et al. Cardiovasc Revasc Med. 2014 Mar;15(2):86-91. End Stage Renal Disease (ESRD) including renal failure on hemodialysis is associated with coronary heart disease and diabetes with subsequent need for revascularization that in this special population has a high...
Reference: Circulation. 2012; 125:1424–143 Abstract: For many years all efforts applied to the optimization of percutaneous coronary intervention (PCI) were aimed specifically at reducing ischemic events risk through the advent of: 1) new devices (medicated stents), reducing restenosis rates, revascularization and 2) development of new drugs with a potent anti-platelet or anticoagulant such as clopidogrel or,...
Original title: A Controlled Trial of Revascularization in Acute Stroke. Reference: Martin Roubec et al. Radiology. 2012;Epub ahead of print. One of the most crucial forecast factors in patients undergoing acute ischemic stroke, stroke caused by a blockage in a brain artery, is the time window to recanalization. Thrombolytic agents have been proved useful but not always achieve...
Original title: Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. Reference: S.S. Jolly et al. for the TOTAL Investigators. N Engl J Med. 2015 Apr 9;372(15):1389-98. Manual thrombectomy is a routine procedure with ST elevation AMI patients. This common practice proved to reduce mortality in the TAPAS study. However, the TASTE study did not observe...
Original title: Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization Results From the EXPERT CTO (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions) Multicenter Trial. Reference: David E. Kandzari et al. J Am Coll Cardiol Intv. 2015, on line before print. The aim of this study was to evaluate...
Original title: Clinical Presentation and Outcomes of Coronary In-Stent Restenosis Across 3-Stent Generations. Reference: Marco A. Magalhaes et al. Circ Cardiovasc Interv. 2014;7:00-00. Studies evaluating the clinical presentation of restenosis after implantation of bare metal stent showed that the recurrence of stenosis is not a benign complication as previously thought, with a significant number of patients with restenosis...
Original title: Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease 12-Month Results From the IN.PACT SFA Randomized Trial. Reference: Gunnar Tepe et al. Circulation. 2015;131:495-502. This interesting study randomly selected 331 patients with intermittent claudication or ischemic rest pain due to stenosis of the superficial femoral artery or...